PAHC
NASDAQ · Pharmaceuticals
Phibro Animal Health Corp-A
$33.50
-1.90 (-5.37%)
Financial Highlights (FY 2026)
Revenue
1.59B
Net Income
104.44M
Gross Margin
33.3%
Profit Margin
6.6%
Rev Growth
+15.8%
D/E Ratio
1.90
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 33.3% | 33.3% | 36.7% | 36.7% |
| Operating Margin | 12.8% | 11.5% | 35.4% | 32.2% |
| Profit Margin | 6.6% | 6.2% | 25.7% | 26.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.59B | 1.37B | 1.31B | 972.76M |
| Gross Profit | 529.95M | 457.68M | 479.67M | 357.06M |
| Operating Income | 203.68M | 158.31M | 462.06M | 312.99M |
| Net Income | 104.44M | 81.18M | 335.32M | 253.19M |
| Gross Margin | 33.3% | 33.3% | 36.7% | 36.7% |
| Operating Margin | 12.8% | 11.5% | 35.4% | 32.2% |
| Profit Margin | 6.6% | 6.2% | 25.7% | 26.0% |
| Rev Growth | +15.8% | +15.8% | +2.9% | -6.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 470.92M | 470.92M | 399.08M | 413.63M |
| Total Equity | 247.72M | 247.72M | 1.04B | 1.11B |
| D/E Ratio | 1.90 | 1.90 | 0.38 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 257.56M | 211.31M | 482.41M | 394.81M |
| Free Cash Flow | — | — | 282.39M | 183.99M |